Real-World Outcome Analysis of Patients With Stage IV NSCLC Treated With Tyrosine Kinase and Immune Checkpoint Inhibitors.
A tyrosine kinase inhibitor
Immune checkpoint inhibitor
Long-term survival data
Non–small cell lung cancer
Real-world
Journal
JTO clinical and research reports
ISSN: 2666-3643
Titre abrégé: JTO Clin Res Rep
Pays: United States
ID NLM: 101769967
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
11
01
2023
revised:
31
03
2023
accepted:
27
04
2023
medline:
10
7
2023
pubmed:
10
7
2023
entrez:
10
7
2023
Statut:
epublish
Résumé
Only a few reports have determined whether recently advanced anticancer drugs, particularly next-generation tyrosine kinase inhibitors (TKIs) and immune checkpoint inhibitors (ICIs), prolong the survival of patients with NSCLC in the real world. To evaluate the association between recently advanced drugs and patient survival, survival data of 2078 patients with stage IV NSCLC from 1995 to 2022 were analyzed in the present study. The patients were classified into the following six groups in terms of the date of diagnosis: period A, 1995 to 1999; period B, 2000 to 2004; period C, 2005 to 2009; period D, 2010 to 2014; period E, 2015 to 2019; and period F, 2000 to 2022. They were further grouped in terms of The median overall survival (mOS) times were 8.9, 11.0, 13.6, 17.9, and 25.2 months in periods A to E, respectively, and the mOS time was not reached in period F. This time was significantly longer in period E than in period D (25.2 versus 17.9 mo, The survival of patients with NSCLC was improved from period D to period E, regardless of the presence of driver gene alteration. We found that next-generation TKIs and ICIs may be associated with improvements in overall survival.
Identifiants
pubmed: 37426307
doi: 10.1016/j.jtocrr.2023.100524
pii: S2666-3643(23)00063-2
pmc: PMC10329142
doi:
Types de publication
Journal Article
Langues
eng
Pagination
100524Informations de copyright
© 2023 The Authors.
Références
PLoS One. 2011;6(8):e22681
pubmed: 21829644
N Engl J Med. 2020 Aug 13;383(7):640-649
pubmed: 32786189
Curr Oncol. 2020 Dec 04;28(1):60-68
pubmed: 33704175
N Engl J Med. 2020 Oct 1;383(14):1328-1339
pubmed: 32997907
Lancet Oncol. 2010 Feb;11(2):121-8
pubmed: 20022809
BMC Cancer. 2022 Mar 10;22(1):255
pubmed: 35264135
N Engl J Med. 2017 Feb 16;376(7):629-640
pubmed: 27959700
N Engl J Med. 2019 Nov 21;381(21):2020-2031
pubmed: 31562796
N Engl J Med. 2020 Aug 27;383(9):813-824
pubmed: 32846060
JAMA Oncol. 2023 Mar 1;9(3):334-341
pubmed: 36701150
J Thorac Oncol. 2022 Mar;17(3):353-361
pubmed: 35216731
Lancet. 2021 Jan 30;397(10272):375-386
pubmed: 33485464
Ann Oncol. 2019 Aug 1;30(8):1321-1328
pubmed: 31125062
N Engl J Med. 2010 Jun 24;362(25):2380-8
pubmed: 20573926
N Engl J Med. 2020 Sep 3;383(10):931-943
pubmed: 32469185
Cochrane Database Syst Rev. 2010 May 12;(5):CD007309
pubmed: 20464750
N Engl J Med. 2020 Jan 2;382(1):41-50
pubmed: 31751012
Lancet. 2017 Jan 21;389(10066):255-265
pubmed: 27979383
BMC Cancer. 2020 Mar 30;20(1):260
pubmed: 32228520
N Engl J Med. 2015 Oct 22;373(17):1627-39
pubmed: 26412456
Clin Lung Cancer. 2019 Jul;20(4):287-296.e4
pubmed: 31130450
J Natl Compr Canc Netw. 2022 May;20(5):497-530
pubmed: 35545176
Lung Cancer. 2019 May;131:69-77
pubmed: 31027701
Cancer Med. 2022 Jan;11(1):86-93
pubmed: 34786889
ESMO Open. 2022 Apr;7(2):100406
pubmed: 35219245
JAMA. 2014 May 21;311(19):1998-2006
pubmed: 24846037
Lancet Oncol. 2013 Jun;14(7):590-8
pubmed: 23639470
N Engl J Med. 2015 Jul 9;373(2):123-35
pubmed: 26028407